Bullboard - Stock Discussion Forum Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s): MDNAF

Healthcare Biotechnology

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior... see more

Add To Watchlist

TSX:MDNA - Post Discussion

Medicenna Therapeutics Corp > Research Capital price target of $6.90

View:

Post by HarryGluten on Nov 17, 2021 6:42am

Research Capital price target of $6.90

$mdna

Canadian biotech company Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart, News TSX:MDNA) has lost a lot of ground in 2021 but analyst Andre Uddin of Research Capital Corp is maintaining an optimistic stance on the company. In an update to clients on Friday, Uddin left his “Speculative Buy” rating and target price of $6.90 target price unchanged, representing at press time a projected 12-month return of 170 per cent.

https://www.cantechletter.com/2021/11/big-catalyst-coming-up-for-medicenna-therapeutics-says-research-cap/#

368